Rosen Law Firm, a global investor rights law firm, announces it is investigating potential securities claims on behalf of shareholders of Sage Therapeutics, Inc. (NASDAQ:SAGE) resulting from allegations that Sage Therapeutics may have issued materially misleading business information to the investing public.

On March 23, 2016, Kerrisdale Capital published a report on Sage Therapeutics asserting that Sage Therapeutics' lead experimental product candidate SAGE-547—indicated for super-refractory status epilepticus (SRSE)—is not a novel breakthrough as Sage Therapeutics touted for its high-level mechanism of action is exactly the same as that of standard drugs like benzodiazepines, anti-epileptics, and anesthetics, which are already used to treat SRSE. The report also asserts that Sage Therapeutics is overestimating the size of the drug's target market by perhaps a factor of 6. On this news, shares of Sage Therapeutics fell sharply during intraday trading on March 23, 2016.

Rosen Law Firm is preparing a class action lawsuit to recover losses suffered by Sage Therapeutics investors. If you purchased shares of Sage Therapeutics on or before March 22, 2016, please visit the firm's website at for more information. You may also contact Phillip Kim, Esq. or Kevin Chan, Esq. of Rosen Law Firm toll free at 866-767-3653 or via email at or

Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.

Attorney Advertising. Prior results do not guarantee a similar outcome.

View source version on

Copyright Business Wire 2010